Quick Takeaways
- WASATCH ADVISORS LP filed SCHEDULE 13G/A for C4 Therapeutics Inc COM STK (CCCC).
- Disclosed ownership: 6.8%.
- Date of event: 30 Sep 2025.
WASATCH ADVISORS LP - 30 Sep 2025 SCHEDULE 13G/A Report for C4 Therapeutics Inc COM STK (CCCC)
- Filing Manager
- WASATCH ADVISORS LP
- Reporting Manager
- Wasatch Advisors LP
- Security
- C4 Therapeutics Inc COM STK
- Symbol
- CCCC
- Shares outstanding
- 71,363,838 shares
- Disclosed Ownership
- 4,852,741 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Nov 2025, 17:33:40 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 07 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"WASATCH ADVISORS LP disclosed 6.8% ownership in C4 Therapeutics Inc COM STK (CCCC) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 07 May 2025.
- Current filing was accepted on 13 Nov 2025, 17:33.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Wasatch Advisors LP | 6.8% | 4,852,741 | 4,312,039 | 0 | Mike Yeates | CEO |